antibodies

“What we're able to see is that, you know, you can search ESMC and you can actually find antibodies that are reaching the level of affinity that are, I should say, are really at the level of affinity that is needed for therapeutic function and activity.”

“And I think, like, one of the things that's really exciting about where we're getting to with some of these models is we can start to get that precise, right? Epitope, right? Meaning like binding spot, right? A very specific set of atoms to have the antibody g…”

“The ultimate goal here is to design medicines, right, and design new molecules, and I think CHI-2 really crossed the threshold of performance for doing that with antibodies a year ago.”

“So we designed antibodies to 50 targets for that paper, got binders to about half of them with being on average around a 20% hit rate for binding.”